Novel anti-brain tumor cytotoxins specific for cancer cells

Nature Biotechnology

Volumn 16, Issue 5, 1998, Pages 449-453

  Debinski, Waldemar ^a   Gibo, Denise M ^a   Obiri, Nicholas I ^a   Kealiher, Aynsley ^a   Puri, Raj K ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Anticancer therapeutics; Fusion proteins; Glioblastoma; Interleukin 13; Mutations; Receptors; Tumor specificity

Indexed keywords

CYTOTOXIN; HYBRID PROTEIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; PSEUDOMONAS EXOTOXIN; RECOMBINANT PROTEIN;

ADOLESCENT; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; FEMALE; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN TARGETING; RECOMBINANT DNA TECHNOLOGY;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL DIVISION; CYTOTOXINS; EXOTOXINS; GLIOMA; GLUTAMIC ACID; HUMANS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; LYSINE; MUTATION; PLASMIDS; PSEUDOMONAS AERUGINOSA; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0031898505     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0598-449     Document Type: Article

References (44)

1. Debinski, W., Obiri. N.I., Powers, S.K., Pastan, I., and Puri, R.K. 1995. Human glioma cells overexpress receptor for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clinical Cancer Research 1:1253-1258.
2. Debinski, W., Miner, R., Leland, P., Obiri, N.I., and Puri, R.K. 1996. Receptor for IL13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem. 271:22428-22433.
3. Debinski, W., Obiri, N.I., Pastan, I., and Puri, R.K. 1995. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. 270:16775-16780.
4. Debinski, W., Gibo, D.M., and Puri, R.K. A novel way to identify a human glioblastoma-specific receptor for targeting. Int. J. Cancer. In press.
5. Obiri, N.I., Debinski, W., Leonard, W.J., and Puri, R.K. 1995. Receptor for interleukin 13: Interaction with interleukin 4 by a mechanism that does not involve the common y subunit of interleukins 2, 4, 7 and 15 receptor. J. Biol. Chem. 270:8797-8804.
6. Obiri, N.I., Husain, S.R., Debinski, W., and Puri, R.K. 1996. Interleukin 13 inhibits growth of human cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin. Cancer Res. 2:1743-1749.
7. Puri, R.K., Leland, P., Obiri, N.I., Husain, S.R., Kreitman, R.J., Haas, G.P. et al. 1996. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin 13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 87:4333-4339.
8. Obiri, N.I., Leland, P., Murata, T., Debinski, W., and Puri, R.K. 1997. The IL13 receptor structure differs on various cell types and. may share more than one component with IL4 receptor. J. Immunol. 158:756-764.
9. Husain, S.R., Obiri, N.I., Gill, P., Zheng, T., Pastan, I., Debinski, W., and Puri, R.K. 1997. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin. Cancer Res. 3:151-156.
10. Pastan, I., Chaudhary, V.K., and Fitzgerald, D. 1992. Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem. 61:331-354.
11. Youle, R.J. 1996. Immunotoxins for central nervous system malignancy. Semin. Cancer Biol. 7:65-70.
12. Shaw, J.P., Akiyoshi, D.E., Arrigo, D.A., Rhoad, A.E., Sullivan, B., Thomas, J. et al. 1991. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. Biol. Chem. 266:21118-21124.
13. Phillips, P.C., Levow, C., Catterall, M., Colvin, O.M., Pastan, I., and Brem, H. 1994. Transforming growth factors-a-Pseudomonas exotoxin fusion protein (TGF-a-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res. 54:1008-1015.
14. Gray, B.L, Smith, D.H., Baldridge, J.S., Harkins, R.N., Vasil, M.L., Chen, E.Y. et al. 1984. Cloning, nucleotide sequence and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA 81:2645-2649.
15. Allured, VS., Collier, R.J., Carroll, S.F., and McKay, D.B. 1986. Structure of exo-toxin A of Pseudomonas aeruginosa at 3.0 Angstrom resolution. Proc. Natl. Acad. Sci. USA 83:1320-1324.
16. Kounnas, M.Z., Morris, R.E., Thompson, M.R., Fitzgerald, D.J., Strickland, O.K., and Saelinger, C.B. 1992. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J. Biol. Chem. 267:12420-12423.
17. Inocencio, N.M., Moehring, J.M., and Moehring, T.J. 1994. Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro. J. Biol. Chem. 269:31831-31835.
18. Ogata, M., Chaudhary, V.K., Pastan, I., and Fitzgerald, D.J. 1990. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J. Biol. Chem. 265:20678-20686.
19. Iglewski, B.H. and Kabat, D. 1975. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc. Natl. Acad. Sci. USA 72:2284-2288.
20. Zurawski, S.M., Vega, F. Jr., Huyghe, B., and Zurawski, G. 1993. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J. 12:2663-2670.
21. Zurawski, S.M., Chomarat, P., Djossou, O., Bidaud, C., McKenzie, A.N.J., Miossec, P. et al. 1995. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J. Biol. Chem. 270:13869-13878.
22. Tony, H.-P, Shen, B.-J., Reusch, P., and Sebald, W. 1994. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13dependent responses in T-cells and B-cells with high efficiency. Eur. J. Biochem. 225:659-665.
23. Vita, N., Lefort, S., Laurent, P., Caput, D., and Ferrara, P. 1995. Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types. J. Biol. Chem. 270:3512-3517.
24. Kruse, N., Tony, H.P., and Sebald, W. 1992. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J. 11:3237-3244.
25. Kruse, N., Shen, B.J., Arnold, S., Tony, H.-P., Muller, T., and Sebald, N. 1992. Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation. EMBOJ. 12:5121-5129.
26. Schnyder, B., Lugli, S., Feng, N., Euer, H., Lutz, R.A., Ryffel, B. et al. 1996. Interleukin-4 (IL4) and IL13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common ( chain. Blood 87:4286-4295.
27. Miloux, B., Laurent, P., Bonnin, O., Lupker, J., Caput, D., Vita, N., Ferrara, P. 1997. Cloning of the human IL13Ra of a functional IL4/IL13 receptor. FEBS Lett. 401:163-166.
28. Idzerda, R.L., March, C.J., Mosley, B., Lyman, S.D., Vanden Bos, T, Gimpel, S.D. et al. 1990. Human interleukin-4 receptor confers biological responsiveness and defines a novel receptor superfamily. J. Exp. Med. 171:861-873.
29. Russell, S.M., Keegan, A.D., Harada, N., Nakamura, Y, Noguchi, M., Leland, P. et al. 1993. lnterIeukin-2 receptor y chain: a functional component of the interleukin-4 receptor. Science 262:1880-1883.
30. Duschl, A. 1995. An antagonistic mutant of interteukin-4 fails to recruit y into the receptor complex. Eur. J. Biochem. 228:305-310.
31. Schnarr, B., Ezernieks, J., Sebald, W., and Duschl, A. 1997. IL4 receptor complexes containing or lacking the y chain are inhibited by an overlapping set of antagonistic IL4 mutant proteins. Int. Immunol. 9:861-868.
32. Bochner, B.S., Klunk, DA, Sterbinsky, S.A., Coffman, R.L, and Schleimer, R.P. 1995. IL13 selectively induces vascular cell adhesion molecuIe-1 expression in human endothelial cells. J. Immunol. 154:799-803.
33. Sironi, M., Sciacca, F.L., Matteucci, C., Conni, M., Vecchi, A., Bernasconi, S. et al. 1994. Regulation of endothelial and mesothelial cell function by interleukin-13: Selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood 84:1913-1921.
34. Caput, D., Laurent, P., Kaghad, M., Lelias, J.-M., Lefort, S., Vita, N., and Ferrara, P. 1996. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor a chain. J. Biol. Chem. 271:16921-16926.
35. Murata, T., Obiri, N.I., Debinski, W., and Puri, R.K. 1997. Structure of IL13 receptor: analysis of subunit composition in cancer and immune cells. Biochem. Biophys. Res. Commun. 238:92-94.
36. Seetharam, S., Chaudhary, V.K., FitzGerald, D.J., and Pastan 1.1991. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem. 266:17376-17381.
37. Kreitman, R.J., Puri, R.K., and Pastan, 1.1994. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc. WarJ. Acad. Set. USA 91:6889-6893.
38. Chinnasamy, N., Rafferty, J.A., Hickson, I., Ashby, J., Tinwell, H., Margison, G.P. et al. 1997. O'-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood 89:1566-1573.
39. Debinski, W., Karlsson, B., Lindholm, L., Siegall, C.B., Willingham, M.C., FitzGerald, D., and Pastan, I. 1992. Monoclonal antibody C242-Pseudomonas exotoxin A: A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice. J. Clin. Invest. 90:405-411.
40. Studier, F.W. and Moffat, B.A. 1986. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189:113-130.
41. Debinski, W., Puri, R.K., Kreitman, R.J., and Pastan, I. 1993. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J. Biol. Chem. 268:14065-14070.
42. Wersall, P., Ohlsson, l., Biberfeld, P., Collins, V., von Krusenstjerna, S., Larsson, S. et al. 1997. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol. Immunother. 44:157-164.
43. Laske, D.W., Youle, R.J., and Oldfield, E.H. 1997. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med. 3:1362-1368.
44. Rutter, C.M. and Elashoff, R.M. 1994. Analysis of longitudinal data: Random coefficient regression modeling. Stat. Med. 13:1211-1231.